عقار جديد للسمنة يعمل بأسلوب حصان طروادة يعزز فقدان الوزن لدى الفئران

8 مايو، 2026

من إعداد الذكاء الاصطناعي

طور علماء علاجاً هجيناً للسمنة يستخدم إشارات GLP-1 و GIP لإيصال مادة معززة لعمليات الأيض مباشرة إلى داخل الخلايا. وأظهرت الاختبارات الأولية على الفئران فقداناً أكبر للوزن وتحكماً أفضل في مستويات السكر في الدم مقارنة بالعلاجات القياسية. ويهدف هذا النهج إلى تقليل الآثار الجانبية من خلال حصر تأثير الدواء في مناطق مستهدفة فقط.

ابتكر باحثون في مركز هيلمهولتز بميونخ هذا المركب عبر ربط جزيء قائم على الإنكريتين بمادة لانيفيبرا نور (lanifibranor)، وهي منشط لمستقبلات PPAR. يعمل التصميم بأسلوب حصان طروادة، مما يسمح للدواء الإضافي بدخول الخلايا عبر مستقبلات GLP-1 أو GIP قبل تفعيل مفاتيح تنظم أيض الدهون والسكر داخل نواة الخلية.

Study finds people who use Ozempic-like drugs for weight loss face added stigma

5 مايو، 2026 من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي تم التحقق من الحقائق

People who lose weight using GLP-1 medications such as Ozempic and Wegovy may be judged more negatively than those who lose weight through diet and exercise — and even more negatively than people who do not lose weight at all — according to a new study led by Rice University psychologist Erin Standen.

Cochrane reviews assess GLP-1 drugs for obesity treatment

Three Cochrane reviews commissioned by the World Health Organization evaluate GLP-1 receptor agonists like tirzepatide, semaglutide, and liraglutide for weight loss in people with obesity. The drugs show substantial weight reduction compared to placebo, but researchers note limitations in long-term data and industry funding influences. Side effects such as nausea are common, raising questions about broader access and safety.

India today investigation reveals lax drug norms for weight loss injections

13 فبراير، 2026 من إعداد الذكاء الاصطناعي

An investigation by India Today highlights how weak enforcement of regulations allows easy access to prescription-only weight-loss drugs in India, leading to increased misuse.

آسيا

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

صحة

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

صحة

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Researchers at Vanderbilt Health discovered that both popular weight loss drugs and bariatric surgery significantly reduce fat mass while causing modest losses in fat-free mass, including muscle, in patients with obesity. The findings, based on over 3,000 patients, show improvements in overall body composition over 24 months. Maintaining this balance is crucial for long-term health, the study emphasizes.

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

22 أبريل، 2026 من إعداد الذكاء الاصطناعي تم التحقق من الحقائق

Researchers in Barcelona report that the lipid drug pemafibrate and the blood-pressure medicine telmisartan reduced diet-induced liver fat in rats and in a zebrafish model of fatty liver disease, with a half-dose combination performing as well as full doses of either drug alone. The work, published in Pharmacological Research, also describes a role for the PCK1 protein in telmisartan’s liver effects and argues that clinical trials would be needed to confirm any benefit in people.

University of Utah researchers identify enzyme PapB that can “lock” GLP-1-like peptides into ring structures

University of Utah scientists report that a radical SAM enzyme known as PapB can join the ends of certain therapeutic peptides to form stable, ring-shaped structures. In experiments described in ACS Bio & Med Chem Au, the enzyme macrocyclized GLP-1-like peptides—including versions containing nonstandard amino acids found in some modern incretin drugs—an approach the researchers say could help make GLP-1 medicines such as semaglutide (Ozempic and Wegovy) more resistant to breakdown.

AI digital twins help manage diabetes and obesity

17 فبراير، 2026 من إعداد الذكاء الاصطناعي

Silicon Valley startup Twin Health uses AI and wearable sensors as an alternative to expensive GLP-1 drugs for weight management. Retired firefighter Rodney Buckley lost 100 pounds in under a year through the program. His experience highlights a shift toward personalized health tech for chronic conditions.

08 مايو 2026 01:19

عقار جديد للسمنة يعمل بأسلوب حصان طروادة يعزز فقدان الوزن لدى الفئران

مقالات ذات صلة

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Cochrane reviews assess GLP-1 drugs for obesity treatment

India today investigation reveals lax drug norms for weight loss injections

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Cleveland Clinic study finds limited weight regain after stopping GLP-1 drugs

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

University of Utah researchers identify enzyme PapB that can “lock” GLP-1-like peptides into ring structures

AI digital twins help manage diabetes and obesity

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Swedish team restores blood sugar control in diabetic mice

Study links Ozempic to lower depression and anxiety risks

Gut reset procedure limits weight regain after stopping Ozempic

Researchers map hindbrain circuit through which hormone FGF21 drives weight loss in obese mice

Study finds prediabetes remission possible without weight loss

GLP-1 weight loss drugs boost premium chocolate sales

Animal study raises new questions about gut effects of SNAC, an ingredient used in oral semaglutide tablets

Scientists identify body's natural off switch for inflammation

New study offers hope for weight loss drugs against alcoholism

يستخدم هذا الموقع ملفات تعريف الارتباط